Tao Li1, Liang Gao1, Peng Chen1, Siyuan Bu1, Dehong Cao1, Lu Yang2, Qiang Wei3. 1. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, China. 2. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, China. wycleflue@163.com. 3. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, China. weiqiang163163@163.com.
Abstract
PURPOSE: To assess the efficacy of intranasal luteinizing hormone-releasing hormone (LHRH) therapy for cryptorchidism. MATERIALS AND METHODS: Eligible studies were identified by two reviewers using PubMed, Embase, and Web of Science databases. Primary outcomes were complete testicular descent rate, complete testicular descent rate for nonpalpable testis, and pre-scrotal and inguinal testis. Secondary outcomes included testicular descent with different medicines strategy and a subgroup analysis. RESULTS: Pooled data including the 1255 undescended testes showed that complete testicular descent rate was 20.9 % in LHRH group versus 5.6 % in the placebo group, which was significantly different [relative risk (RR) 3.94, 95 % confidence interval (CI) 2.14-7.28, P < 0.0001]. There was also a significant difference in the incidence of pre-scrotal and inguinal position testis descent, with 22.8 % in the LHRH group versus 3.6 % in the placebo group (RR 5.79, 95 % CI 2.94-11.39, P < 0.00001). However, side effects were more frequent in the LHRH group (RR 2.61, 95 % CI 1.52-4.49, P = 0.0005). There were no significant differences for nonpalpable testes. CONCLUSIONS: LHRH had significant benefits on testicular descent, particularly for inguinal and pre-scrotal testes, which was also accompanied by temporary slight side effects.
PURPOSE: To assess the efficacy of intranasal luteinizing hormone-releasing hormone (LHRH) therapy for cryptorchidism. MATERIALS AND METHODS: Eligible studies were identified by two reviewers using PubMed, Embase, and Web of Science databases. Primary outcomes were complete testicular descent rate, complete testicular descent rate for nonpalpable testis, and pre-scrotal and inguinal testis. Secondary outcomes included testicular descent with different medicines strategy and a subgroup analysis. RESULTS: Pooled data including the 1255 undescended testes showed that complete testicular descent rate was 20.9 % in LHRH group versus 5.6 % in the placebo group, which was significantly different [relative risk (RR) 3.94, 95 % confidence interval (CI) 2.14-7.28, P < 0.0001]. There was also a significant difference in the incidence of pre-scrotal and inguinal position testis descent, with 22.8 % in the LHRH group versus 3.6 % in the placebo group (RR 5.79, 95 % CI 2.94-11.39, P < 0.00001). However, side effects were more frequent in the LHRH group (RR 2.61, 95 % CI 1.52-4.49, P = 0.0005). There were no significant differences for nonpalpable testes. CONCLUSIONS:LHRH had significant benefits on testicular descent, particularly for inguinal and pre-scrotal testes, which was also accompanied by temporary slight side effects.
Authors: Helena E Virtanen; Robert Bjerknes; Dina Cortes; Niels Jørgensen; Ewa Rajpert-De Meyts; Arni V Thorsson; Jørgen Thorup; Katharina M Main Journal: Acta Paediatr Date: 2007-05 Impact factor: 2.299
Authors: Thomas F Kolon; C D Anthony Herndon; Linda A Baker; Laurence S Baskin; Cheryl G Baxter; Earl Y Cheng; Mireya Diaz; Peter A Lee; Carl J Seashore; Gregory E Tasian; Julia S Barthold Journal: J Urol Date: 2014-05-20 Impact factor: 7.450
Authors: E Martin Ritzén; A Bergh; R Bjerknes; P Christiansen; D Cortes; S E Haugen; N Jörgensen; C Kollin; S Lindahl; G Läckgren; K M Main; A Nordenskjöld; E Rajpert-De Meyts; O Söder; S Taskinen; A Thorsson; J Thorup; J Toppari; H Virtanen Journal: Acta Paediatr Date: 2007-02-26 Impact factor: 2.299
Authors: Michael E Chua; Jonathan S Mendoza; Michael John V Gaston; Saturnino L Luna; Marcelino L Morales Journal: J Pediatr Surg Date: 2014-07-25 Impact factor: 2.545
Authors: J Rajfer; D J Handelsman; R S Swerdloff; R Hurwitz; H Kaplan; T Vandergast; R M Ehrlich Journal: N Engl J Med Date: 1986-02-20 Impact factor: 91.245
Authors: L H Olsen; H G Genster; A Mosegaard; F S Jørgensen; N Hofman; V B Jensen; L B Lassen; M Rassmussen; L Vinzents; L Dammegaard Journal: Int J Androl Date: 1992-04
Authors: Wiwat Rodprasert; Helena E Virtanen; Juho-Antti Mäkelä; Jorma Toppari Journal: Front Endocrinol (Lausanne) Date: 2020-01-15 Impact factor: 5.555